kabutan

HEALIOS K.K.(4593) Summary

4593
TSE Growth
HEALIOS K.K.
432
JPY
+21
(+5.11%)
Dec 5, 12:46 pm JST
2.78
USD
Dec 4, 10:46 pm EST
Result
PTS
outside of trading hours
432
Dec 5, 12:46 pm JST
Summary Chart Historical News Financial Result
PER
PBR
17.0
Yield
ー%
Margin Trading Ratio
18.69
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
413 JPY 2.66 USD
Previous Close Dec 4
411 JPY 2.64 USD
High Dec 5, 11:05 am
438 JPY 2.82 USD
Low Dec 5, 9:00 am
413 JPY 2.66 USD
Volume
1,744,000
Trading Value
0.74B JPY 4.78M USD
VWAP
425.43 JPY 2.74 USD
Minimum Trading Value
43,200 JPY 278 USD
Market Cap
0.05T JPY 0.32B USD
Number of Trades
1,089
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
2,792
1-Year High Jul 17, 2025
31,879
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 1,534,800 14,171,200 9.23
Nov 21, 2025 1,564,900 13,836,800 8.84
Nov 14, 2025 1,587,700 13,639,200 8.59
Nov 7, 2025 1,612,700 15,691,100 9.73
Oct 31, 2025 1,785,100 15,664,200 8.77
Company Profile
HEALIOS K.K. develops treatments for intractable diseases using iPS cells. The company collaborates with Sumitomo Pharma and has a business alliance with Nikon.
Sector
Pharmaceuticals
HEALIOS K.K. conducts research and development of regenerative medicine products utilizing iPS cell technology. In the field of somatic stem cell regenerative medicine, the company is advancing the development of HLCM051 for acute cerebral infarction and ARDS (Acute Respiratory Distress Syndrome). In the iPSC regenerative medicine field, which involves transplanting cells with functions similar to the human body created by differentiating iPS cells, HEALIOS K.K. is developing a next-generation platform to create Universal Donor Cells (UDC) with reduced risk of immune rejection. The company's pipeline includes research and development in cancer immunotherapy, age-related macular degeneration treatment, and liver disease treatment. Through joint development with Sumitomo Pharma and collaborations with domestic and international research institutions, HEALIOS K.K. aims to realize new treatments for intractable diseases.